Growth stimulating factor in patients with comorbid pathology

   Objective: to study the level of growth stimulating factor (sST-2) in comorbid patients with ST-segment elevation myocardial infarction (STeMI) who underwent PCI for 36 months.

   Materials and methods: the study included 191 people, 36.2 + 1.8 months of follow-up, and included the following stages: I stage (hospital) — from the moment of admission to the hospital for myocardial infarction; II stage (outpatient) — repeated visits 12 and 36 months after discharge from the hospital. The patients were divided into three groups: Group 1 — 69 patients with STEMI + hypertension; Group 2 — 67 patients with STEMI + hypertension + type 2 diabetes; Group 3 (comparison group) — 55 patients with hypertension and DM. Assessment of the plasma level of sST2 was carried out using kits of the company «Critical Diagnostics Presage RST2 Assay kit» (USA). The results were expressed in ng/ml.

   Results: the study showed that the level of the sST2 biomarker in patients with acute ST-segment elevation myocardial infarction(STEMI) and type 2 diabetes mellitus(DM2) had no significant differences between the groups. The sST2 values in these patients were significantly higher than in the comparison group. At the stage of hospitalization, the median sST2 in the first group (STEMI and HYPERTENSION) was 62.7 ng/ml, and in the second group (STEMI, hypertension and DM 2) — 56.3 ng / ml. After one year, the median decreased to 55.3 ng/ml and 52.4 ng/ml, respectively, and in the third year — to 46.4 ng/ml and 42.1 ng/ml. Correlations between sST2 values were not found in the acute period and after 12 and 36 months of pregnancy. A moderate association appeared in the 1st and 3rd year of follow-up.

   Conclusion: the study revealed that the level of the sST-2 marker in the groups of patients with STEMI\ + AH and STeMI + AH + DM at all stages of the study is comparable and significantly higher than in patients with hypertension + DM. During the study, a correlation was found between the levels of sST-2 outside the acute period of MI. However, there was no significant association between the marker levels at the hospital stage and its values at the end of the study. It was also found that the level of sST\-2 does not depend on the presence of diabetes and is associated with the final systolic, diastolic size and volume of.

1. Wang XY, Zhang F, Zhang C, Zheng LR, Yang J. The Biomarkers for Acute Myocardial Infarction and Heart Failure. Biomed Res Int. 2020;2020:2018035. DOI: 10.1155/2020/2018035

2. Jha D, Goenka L, Ramamoorthy T, Sharma M, Dhandapani VE, George M. Prognostic role of soluble ST2 in acute coronary syndrome with diabetes. Eur J Clin Invest. 2018;48(9):e12994. DOI: 10.1111/eci.12994

3. Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I., et al. 2024 Clinical practice guidelines for Hypertension in adults. Russian Journal of Cardiology. 2024;29(9):6117. (In Russ.) Kobalava W. D., Konradi A. O., Nedogoda S. V., Shlyakhto E. V., Arutyunov G. P., Baranova E. I. and others. Arterial hypertension in adults. Clinical Guidelines 2024. Russian Journal of Cardiology. 2024;29(9):6117. DOI: 10.15829/1560-4071-2024-6117. EDN: GUEWLU

4. Bokovikov I.F., Protasov K.V. Prediction of in-hospital mortality in patients with myocardial infarction and type 2 diabetes: the role of cellular indices of systemic inflammation. Russian Journal of Cardiology. 2024;29(7):5823. (In Russ.) DOI: 10.15829/1560-4071-20245823. EDN: QKKOCJ

5. Dedov I.I., Shestakova M.V., Mayorov A.Y., Shamkhalova M.S., Sukhareva O.Yu., Galstyan G.R., et al. Diabetes mellitus type 2 in adults. Diabetes mellitus. 2020;23(2S):4-102. (In Russ.) DOI: 10.14341/DM12507

6. Nadar SK, Shaikh MM. Biomarkers in Routine Heart Failure Clinical Care. Card Fail Rev. 2019;5(1):50-56. DOI: 10.15420/cfr.2018.27.2

7. Khoroshikh L.V., Khotsanyan C.V., Gromova O.I., Bulaeva N.I. Prognostic value of myocardial injury marker (stimulating growth factor ST2) in patients with acute coronary syndrome. Creative Cardiology. 2021;15(4):468–481 (in Russ.). DOI: 10.24022/1997-3187-2021-15-4-468-481

8. Mueller T, Jaffe AS. Soluble ST2--analytical considerations. Am J Cardiol. 2015;115(7 Suppl):8B-21B. DOI: 10.1016/j.amjcard.2015.01.035